Venöse retinale Gefäßverschlüsse

Hattenbach, Lars‐Olof; Chronopoulos, Argyrios; Feltgen, Nicolas

doi:10.1007/s00347-022-01735-y

Cited by 4 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently topically used nintedanib was proved to inhibit corneal NV in rabbit models [24] . Patients with RVO usually showed higher bFGF and VEGF concentration in aqueous humors, which were parallel with the disease activity [8,[25][26][27][28][29] . Therefore, we postulate that intravitreal injection of nintedanib would inhibit bFGF and VEGF expression elevated by RVO.…”

Section: Introductionmentioning

confidence: 88%

“…Up to date, the mainstream treatment for those disorders is anti-vascular drug administration, such as bevacizumab, ranibizumab and aflibercept, etc [2][3][4] . However, in addition to the pronounced antivascular effect, the ensuing fibrosis may also bring about many severe problems, like retinal pigment epithelium tear, tractional retinal detachment and so on [5][6][7][8][9][10] . The normal angiogenesis process requires a fine balance between the pro-vascular and anti-vascular biomolecules, including angiopoietin 2, vascular endothelial growth factor (VEGF), tumor necrosis factor α (TNFα), platelet derived growth factor (PDGF), and basic fibroblast growth factor (bFGF), etc [11] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model

Fang,

Qian,

et al. 2023

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To evaluate whether a novel tyrosine kinase inhibitor nintedanib could inhibit basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) simultaneously for retinal vascular disease in vivo. METHODS: After a laser induced rabbit retinal vein occlusion (RVO) model was made, 0.5 mg of nintedanib was injected intravitreally in the left eye on the third day while the right eye was as a control. Intracameral samples were taken on the day before laser treatment and days 1, 3, 7, 14, 21, and 28 after treatment. Enzyme-linked immunosorbent assay (ELISA) was used to test the bFGF and VEGF-A concentrations in the aqueous humor. RESULTS: Both bFGF and VEGF-A rose significantly on the third day after laser treatment in both eyes. In the control eye the bFGF concentration peaked on the 14th day while the VEGF-A concentration dropped rapidly soon after the third day. After nintadanib injection in the study eye, both bFGF and VEGF-A showed a significant reduction on the 4th day (7th day after laser treatment) when compared to the control eye, and kept on low level in the following several weeks. CONCLUSION: Intravitreal injection of nintedanib can inhibit the expression of bFGF and VEGF in the process of RVO model to a certain extent, which is expected to become a new method for the treatment of retinal vascular diseases or fibrotic diseases.

show abstract

Section: Introductionmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model

Fang,

Qian,

et al. 2023

Int J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…It is currently the first-line therapy for managing ME in RVO cases [ 3 ]. The efficacy of the mainstream treatment strategies, such as pro re nata (PRN) or treat-and-extend (T&E), depends on the subjective judgment of macular central fovea edema [ 4 ]. It is often challenging for clinicians to predict the efficacy of treatment and determine the follow-up date before treatment because some patients respond poorly to anti-VEGF therapy or experience recurrence after improvement.…”

Section: Introductionmentioning

confidence: 99%

Multimodal deep transfer learning to predict retinal vein occlusion macular edema recurrence after anti-VEGF therapy

Zhang,

Huang,

Chen

et al. 2024

Heliyon

View full text Add to dashboard Cite

Impact of anti-VEGF treatment-free interval during the first year on 5-year outcomes in eyes with branch retinal vein occlusion

Du,

Mayer,

Feistritzer

et al. 2024

European Journal of Ophthalmology

View full text Add to dashboard Cite

Objectives This study aims to analyze the impact of longest treatment-free interval (TFI) between anti-vascular endothelial growth factor (anti-VEGF) injections during the first year of treatment on 5-year best-corrected visual acuity (BCVA) and recurrence of macular edema (ME) in eyes with ME secondary to branch retinal vein occlusion (BRVO). Methods A retrospective study including eyes with BRVO, minimum of 5-year follow-up, and available optical coherence topography (OCT) scans. Eyes underwent anti-VEGF loading dose therapy and were treated and monitored with an OCT-guided PRN regimen. Those with a history of ocular comorbidities were excluded. Results Total of 60 patient eyes, with 40 females and average age of 71.75 ± 11.07 years. TFI among eyes was 1 month (20%); > 1–2 months (23%); > 2–3 months (18%); > 3–4 months (17%), and >4 months (22%). Forty-three (72%) eyes experienced ME recurrence during the five-year period. Multivariate linear regression shows that TFI (−0.02 [-0.03–0.00], p = 0.021) and baseline BCVA (0.37 [0.08–0.66], p = 0.014) are significant predictors of 5-year BCVA. TFI (Cox Proportional Hazard Ratio 1.34 [1.04–1.72], p = 0.023) and number of injections in the first year (Cox Proportional Hazard Ratio 1.76 [1.01–3.06], p = 0.045) were significant predictors of ME recurrence. Gender, age, type of injection, BCVA, and CMT did not influence recurrence. Conclusion For eyes receiving anti-VEGF injections to treat ME secondary to BRVO, TFI is a significant predictor of 5-year BCVA and ME recurrence according to regression models. This study suggests more ME recurrence may be due to increased TFI or indicate more injections needed to treat severe BRVO.

show abstract

Venöse retinale Gefäßverschlüsse

Cited by 4 publications

References 49 publications

Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model

Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model

Multimodal deep transfer learning to predict retinal vein occlusion macular edema recurrence after anti-VEGF therapy

Impact of anti-VEGF treatment-free interval during the first year on 5-year outcomes in eyes with branch retinal vein occlusion

Contact Info

Product

Resources

About